

Atty. Dkt. No. 016777/0528

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Daniel J. DRUCKER**
Title: *Glucagon-Like Peptide-2 And Its
Therapeutic Use*
Appl. No.: **10/042,746**
Filing Date: **November 20, 2002**
Examiner: **Not Yet Assigned**
Art Unit: **1642**

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant submits herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 08/632,533, filed on 04/12/1996. Pursuant to 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 20, 2003

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5538
Facsimile: (202) 672-5399


By

Michele M. Simkin
Michele M. Simkin
Attorney for Applicant
Registration No. 34,717

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	08/632,533
		Filing Date	04/12/1996
Date Submitted: March 20, 2003 (use as many sheets as necessary)		First Named Inventor	Daniel J. Drucker
		Group Art Unit	1642
Sheet 1 of 3		Examiner Name	Not Yet Assigned
		Attorney Docket Number	016777-0528



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,912,229		THIM et al.	06/15/99	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A2	EP	612,531		08/31/94	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	BARRAGAN, et al., Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. <i>American Journal of Physiology</i> . 266 (3 Pt 1), pE459-66, March 1994.	
	A4	BLOOM, et al., Gut Hormones in adaptation. <i>Gut</i> . 28, S1, pp. 31-35, 1987.	
	A5	BRUBAKER, et al., Regulation of Intestinal Proglucagon-Derived Peptide Secretion by Intestinal Regulatory Peptides. <i>Endocrinology</i> . Vol. 128, No. 6, pp. 3175-3182, 1991.	
	A6	BUHL, et al., Naturally Occurring Products of Proglucagon 111-160 in the Porcine and Human Small Intestine. <i>The Journal of Biological Chemistry</i> . Vol. 263, No. 18, pp. 8621-8624, Issue of June 25, 1988.	
	A7	CALVO, et al., Structural characterization by affinity cross-linking of glucagon-like peptide-1 (7-36) amide receptor in rat brain. <i>J. Neurochem</i> . 64(1), pp. 299-306, January 1995.	
	A8	CHEESEMAN, et al., The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal basolateral membrane hexose transport. <i>The American Physiological Society</i> . APSracts 3:0071G, April 16, 1996.	
	A9	DRUCKER, et al., <i>Pancreas</i> . 1990, 5(4):484	
	A10	EHRlich, et al., Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. <i>American Journal of Physiology</i> . pp. E662-E671, 1994.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.986220.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 20, 2003 (use as many sheets as necessary)		Application Number	08/632,533
		Filing Date	04/12/1996
		First Named Inventor	Daniel J. Drucker
		Group Art Unit	1642
		Examiner Name	Not Yet Assigned
Sheet	2	of	3
		Attorney Docket Number	016777-0528



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A11	GEORGE, et al., Molecular forms of glucagon-like peptides in man. <i>FEBS Letters</i> . Vol. 192, No. 2, pp. 275-278, November 1985.	
	A12	HOOSEIN, et al., Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase <i>FEBS Letters</i> . Vol. 178, No. 1, pp. 83-86, December 1984.	
	A13	IRWIN, et al., Trout and Chicken Proglucagon: Alternative Splicing Generates mRNA Transcripts Encoding Glucagon-Like Peptide 2. <i>Molecular Endocrinology</i> . 9:267-277, 1995.	
	A14	LEE, et al., Glucagon Gene 5'-Flanking Sequences Direct Expression of Simian Virus 40 Large T Antigen to the Intestine, Producing Carcinoma of the Large Bowel in Transgenic Mice. <i>The Journal of Biological Chemistry</i> . Vol. 267, No. 15, pp. 10706-10708, May 25, 1992.	
	A15	LUND, et al., Regulation of Intestinal Glucagon Gene Expression during Adaptive Growth of Small Intestine. <i>Digestion</i> . 54:371-373, 1993.	
	A16	MOJISOV, et al., Preproglucagon Gene Expression in Pancreas and Intestine Diversifies at the Level of Post-translational Processing. <i>The Journal of Biological Chemistry</i> . Vol. 261, No. 25, pp. 11880-11889, September 5, 1986.	
	A17	MOMMSEN, et al., Glucagon-like peptides activate hepatic gluconeogenesis. <i>FEBS Letters</i> . Vol. 219, No. 1, pp. 227-232, July 1987.	
	A18	NISHI, et al., <i>Mol. Endocrinol.</i> , 1990, 4:1192-8.	
	A19	ORSKOV, et al., Carboxypeptidase-B-like processing of the C-terminus of glucagon-like peptide-2 in pig and human small intestine. <i>FEBS Letters</i> . 247(2), pp. 193-196, April 24, 1989.	

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.986220.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 20, 2003 (use as many sheets as necessary)		Application Number	08/632,533
		Filing Date	04/12/1996
		First Named Inventor	Daniel J. Drucker
		Group Art Unit	1642
		Examiner Name	Not Yet Assigned
Sheet	3	of	3
		Attorney Docket Number	016777-0528



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A20	ORSKOV, et al., Pancreatic and intestinal processing of proglucagon in man. <i>Diabetologia</i> . 30:874-881, 1987.	
	A21	ORSKOV, et al., Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). <i>Scand. J. Clin. Lab. Invest.</i> 47(2), pp. 165-174, April 1987.	
	A22	ORSKOV, et al., Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas. <i>Endocrinology</i> . Vol. 119, No. 4, pp. 1467-1475, 1986.	
	A23	RUIZ-GRAND, et al., Renal catabolism of human glucagon-like peptides 1 and 2. <i>Can. J. Physiol. Pharmacol.</i> 68 (12), pp. 1568-1573, Dec. 1990.	
	A24	SHENNAN, et al., Proglucagon expression, post-translational processing and secretion in SV40-transformed islet cells. <i>Molecular and Cellular Endocrinology</i> . 67(1989), pp. 93-99.	
	A25	WATANABE, et al., Trophic Effect of Glucagon-(1-21)-Peptide on the Isolated Rat Ileal Mucosal Cells. <i>Biochemical and Biophysical Research Communications</i> . Vol. 152, No.3. pp. 1038-1044, May 16, 1988.	

RECEIVED
MAR 21 2003
TECH CENTER 1600/2900

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.986220.1